Nasolabial Fold Clinical Trial
Official title:
Evaluation of Collagen Dermal Filler With Lidocaine for the Correction of Nasolabial Folds: a Prospective, Randomized, Active-controlled, Double Blinded, Multicenter Clinical Trial
Verified date | January 2019 |
Source | National Taiwan University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Evaluation the efficacy and safety of collagen dermal filler with lidocaine using in the middle to deep dermis for the correction of nasolabial folds.
Status | Active, not recruiting |
Enrollment | 240 |
Est. completion date | August 31, 2020 |
Est. primary completion date | February 28, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Bilateral defects in the nasolabial folds with grades 3 or 4 on the Wrinkle Severity Rating Scale (WSRS). 2. Male or female aged 20 ~ 65-year-old. 3. Willingness to receive wrinkle augment treatment. 4. Willingness to avoid other facial beauty therapy during this clinical trial. 5. Healthy facial skin condition, and not have any disorder that can interfere the assessment of skin aging, e.g. facial nerve disorders. 6. All the enrolled subjects should sign and date the informed consent form before this trial starts. Exclusion Criteria: 1. Known history of anaphylactoid reaction and other auto-immune diseases. 2. Known history of allergies to collagen, or those who are allergic to the control or investigational device after the verification of intradermal allergy test. 3. Known history of allergies to lidocaine. 4. Known coagulation disorders. 5. Females who have positive pregnancy test at screening, plan a pregnancy, breastfeeding, and those who are unable to take contraception method. 6. Subjects with local infection, severity skin disease, inflammation or related symptoms on the nasolabial folds. Or with keloid (hypertrophic scar). 7. Subjects with severe cardiac, renal, hepatic, or respiratory diseases. 8. Subjects with clinically diagnosed mental illness. 9. According to American National Institute of Health standards, those who meet the criteria of Alcohol Use Disorder. 10. Subjects take immunosuppressive drugs, chemotherapy, or systemic steroids (i.e. oral or injection) within 12 weeks before screening. 11. Subjects take anticoagulant treatment or NSAIDs within 1 week before screening. 12. Subjects have permanent implants in the nasolabial folds area. 13. Subjects have nasolabial folds augment treatment such as autologous fat, hyaluronic acid or collagen filler implant within 52 weeks before screening. 14. Subjects have nasolabial fold correctional procedure or treatment such as botulinum toxin injection, chemical peeling, laser at dermis or plastic surgery. 15. Subjects unable to comply the scheduled follow-up. 16. Subjects participate other clinical trials within 12 weeks before screening (trials only with questionnaire or specimen collection are exemption). 17. Subjects who are not eligible for this trial based on the judgment of investigators. |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital | Chang Gung Memorial Hospital, Tri-Service General Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety Endpoint (Evaluation of laboratory inspection values.) | Evaluation of laboratory inspection values. | One year. Number of participants with abnormal laboratory values and/or adverse events that are related to treatment. | |
Other | Safety Endpoint (Evaluation of the percentage of AE and AR) | Evaluation of the percentage of AE and AR | One year. Number of participants with AE divided by number of participants with AR is the percentage of AE and AR. | |
Primary | WSRS score evaluation | 24th week response rate will be calculated according to WSRS score assessed by the evaluators Subtract the subject's WSRS baseline score from the Xth week after injection as improved score. | 24th week. Using the 5-grade Wrinkle Severity Rating Scale (WSRS) to evaluate wrinkle, and score 5 is the worst one. | |
Secondary | WSRS score evaluation within 4 time point as assessed by the evaluators | WSRS response rate at 4th, 12th, 36th and 52nd week as assessed by the evaluators | 4th, 12th, 36th and 52nd week week. Using the 5-grade Wrinkle Severity Rating Scale (WSRS) to evaluate wrinkle, and score 5 is the worst one. | |
Secondary | GAIS score at specific week as assessed by the subject | GAIS score at 4th, 12th, 24th, 36th and 52nd week as assessed by the subject | 4th, 12th, 24th, 36th and 52nd week. Global Aesthetic Improvement Scale (GAIS) is scored 5 level of improvement. Score 5 is the worst value. | |
Secondary | GAIS score at specific week as assessed by the evaluators | GAIS score at 4th, 12th, 24th, 36th and 52nd week as assessed by the evaluators | 4th, 12th, 24th, 36th and 52nd week. Global Aesthetic Improvement Scale (GAIS) is scored 5 level of improvement. Score 5 is the worst value. | |
Secondary | VAS score evaluation | VAS score within 30 mins after injection as assessed by the subject | 30 minutes. Double-sided print or photocopy the next 2 diagrams ensuring that the lines are exactly 10 cm in length and superimposed. | |
Secondary | TPS score evaluation | TPS score within 30 mins after injection as assessed by the investigator | 30 minutes. The score is evaluated by thermometer pain scale, and the scale is 0-10. 0 stands for on pain, and 10 stands for worst possible pain. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04128046 -
The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation
|
N/A | |
Completed |
NCT03174132 -
Pain and Safety of Restylane Perlane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds
|
N/A | |
Completed |
NCT03300466 -
A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds
|
N/A | |
Recruiting |
NCT01848717 -
Evaluate the Efficacy and Safety of MINTLIFT® Group for Nasolabial Fold
|
N/A | |
Completed |
NCT04534660 -
Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler
|
N/A | |
Active, not recruiting |
NCT04839484 -
LifeSprout Luminaâ„¢ Study in the Treatment of Nasolabial Folds
|
N/A | |
Completed |
NCT04754646 -
RHA® 4 NLF Cannula
|
N/A | |
Completed |
NCT02176356 -
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
|
Phase 4 | |
Completed |
NCT02558283 -
A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® for Nasolabial Folds in Chinese Adults
|
N/A | |
Completed |
NCT01775293 -
Clinical Trial to Evaluate the Efficacy and Safety in Nasolabial Fold After Rhytidectomy Using Non-absorbable Mesh
|
N/A | |
Completed |
NCT01585220 -
Efficacy and Safety Study of Neuramis in Correction of Nasolabial Fold
|
Phase 3 | |
Completed |
NCT02918721 -
Pain and Safety of Restylane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds
|
N/A | |
Completed |
NCT05294562 -
China Post-Market Clinical Follow-up of FACILLE®
|
||
Recruiting |
NCT04957446 -
Histology Study of Biostimulatory Activity of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic)
|
N/A | |
Completed |
NCT04569045 -
Evaluate the Safety and Effectiveness of Sodium Hyaluronate When Used for the Correction of Nasolabial Folds
|
N/A | |
Recruiting |
NCT04224649 -
To Evaluate the Efficacy and Safety of Injection With HARA as Compared to Restylane® Lidocaine in Temporary Correction of Nasolabial Folds
|
N/A |